Cash, cash equivalents, and short-term investments totaled approximately $53.7M as of December 31, 2023. “Nana-val is a first-in-class, all-oral combination treatment regimen that has entered late-stage development to target and treat EBV-associated cancers. Our near-term goal is to address the high unmet medical need of patients living with relapsed or refractory EBV-positive PTCL by advancing Nana-val in this lead indication through regulatory approval as quickly as possible,” said Mark Rothera, President and Chief Executive Officer of Viracta. “We are pleased to have successfully completed patient enrollment across both Stage 1 and Stage 2 of the PTCL cohort in our pivotal NAVAL-1 trial. Building on this momentum, we anticipate reporting topline data from Stage 1 in the second quarter of 2024 and engaging with the FDA on a potential accelerated approval pathway in mid-2024.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on VIRX:
- Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Viracta announces completion of second-stage enrollment in NAVAL-1 trial
- Oppenheimer biotech/healthcare analysts hold analyst/industry conference call
- Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue